Antonio Barbieri
Overview
Explore the profile of Antonio Barbieri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1959
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DAmbrosio R, Cavallo S, Brunetti R, Pellicano R, Vaccaro E, Borriello G, et al.
Animals (Basel)
. 2025 Feb;
15(3).
PMID: 39943084
The aim of this research was to investigate the effects of the prolonged use of the broad-spectrum antimicrobial widely used in animal husbandry. By means of a mouse model, a...
2.
Del Vecchio V, Mele L, Panda S, Sanchez-Pajares I, Mosca L, Tirino V, et al.
Cell Death Dis
. 2023 Sep;
14(9):613.
PMID: 37723219
The β2-Adrenergic receptor (β2-ARs) is a cell membrane-spanning G protein-coupled receptors (GPCRs) physiologically involved in stress-related response. In many cancers, the β2-ARs signaling drives the tumor development and transformation, also...
3.
Conte C, Longobardi G, Barbieri A, Palma G, Luciano A, Dal Poggetto G, et al.
Int J Pharm
. 2023 May;
641:123045.
PMID: 37169105
No abstract available.
4.
Campobasso D, Barbieri A, Bocchialini T, Pozzoli G, Dinale F, Facchini F, et al.
Arch Ital Urol Androl
. 2023 Mar;
95(1):11101.
PMID: 36924373
Objective: The major strengths of surgical treatment of benign prostatic hyperplasia with laser are reduced morbidity compared to endoscopic resection. No studies analysed the different risk of intra/peri-operative events between...
5.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al.
Front Cardiovasc Med
. 2023 Feb;
10:1129873.
PMID: 36742077
[This corrects the article DOI: 10.3389/fcvm.2022.930797.].
6.
Conte C, Longobardi G, Barbieri A, Palma G, Luciano A, Dal Poggetto G, et al.
Int J Pharm
. 2023 Jan;
633:122618.
PMID: 36657553
Surface functionalization of nanoparticles (NPs) with tumor-targeting peptides is an emerging approach with a huge potential to translate in the clinic and ameliorate the efficacy of nano-oncologicals. One major challenge...
7.
Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, et al.
Cell Rep
. 2022 Nov;
41(6):111601.
PMID: 36351409
Melanoma is a deadly form of cancer characterized by remarkable therapy resistance. Analyzing the transcriptome of MAPK inhibitor sensitive- and resistant-melanoma, we discovered that APAF-1 is negatively regulated by MITF...
8.
Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al.
Front Cardiovasc Med
. 2022 Sep;
9:930797.
PMID: 36158826
Background: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from...
9.
Giudice A, Aliberti S, Barbieri A, Pentangelo P, Bisogno I, DArena G, et al.
Front Biosci (Landmark Ed)
. 2022 Jul;
27(7):223.
PMID: 35866405
Breast cancer is the most common malignancy among women worldwide. Several studies indicate that, in addition to established risk factors for breast cancer, other factors such as cortisol release related...
10.
Ierano C, Righelli D, DAlterio C, Napolitano M, Portella L, Rea G, et al.
J Immunother Cancer
. 2022 Mar;
10(3).
PMID: 35246475
Background: Colorectal cancer (CRC) is one of the most prevalent and deadly tumors worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based cancer immunotherapy, with approximately 15%...